8-K: Immunic Presents New Phase 2 CALLIPER Trial Data

Immunic, Inc. presented new post-hoc analysis data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis at the 2026 CMSC Annual Meeting.

Summary

• Presented three posters at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting regarding the phase 2 CALLIPER trial.
• Introduced a novel 'Confirmed Disability Change' (CDC) statistical approach to measure both disability worsening and improvement.
• Reported favorable safety and tolerability profiles for vidofludimus calcium (IMU-838) compared to placebo over 120 weeks.
• Patient-reported outcomes showed no negative impact on mood or depressive thoughts compared to placebo.
• Data suggests potential neuroprotective effects of vidofludimus calcium in progressive multiple sclerosis (PMS) patients.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive update; while the data is exploratory and post-hoc, it provides incremental support for the drug's safety and potential efficacy profile ahead of critical phase 3 readouts.

Positives

• Consistent safety and tolerability profile with 69.4% TEAE incidence for vidofludimus calcium vs 68.5% for placebo.
• No significant difference in discontinuation rates due to adverse events (2.6% in both groups).
• Patient-reported treatment effectiveness numerically favored vidofludimus calcium over placebo at weeks 48 and 120.
• Novel CDC statistical approach may improve future trial power and capture treatment benefits more comprehensively.

Negatives

• Data presented are post-hoc analyses, which are exploratory in nature and not primary trial endpoints.
• Vidofludimus calcium remains an investigational drug not yet approved for commercial use in any country.

Risks

• Clinical trial results may not be predictive of future outcomes in larger or different patient populations.
• Regulatory approval process is subject to uncertainty and potential delays.
• Competitive landscape and technological changes could impact the commercial potential of the drug.
• Macroeconomic factors, including inflation and geopolitical conflicts, may impact ongoing clinical operations.

Future Outlook

The company expects top-line data for its phase 3 ENSURE trials in relapsing multiple sclerosis to be available by the end of 2026.

Management Comments

• Daniel Vitt, CEO: 'The new data presented... continues to demonstrate a consistent and differentiated profile for vidofludimus calcium in multiple sclerosis.'
• Michael A. Panzara, CMO: 'These data, combined with a safety and tolerability profile that appears favorable, supports the continued development of vidofludimus calcium for progressive MS.'

Industry Context

StockSavvy.ai notes that Immunic is attempting to differentiate its asset in a crowded MS market by focusing on neuroprotection via Nurr1 activation and a novel statistical approach to disability measurement, which is a common strategy for late-stage biotech firms seeking to improve the probability of regulatory success.

Comparison to Industry Standards

• The use of post-hoc analyses to highlight potential neuroprotective benefits is a standard practice in MS drug development to build a case for phase 3 trial design.
• The safety profile (TEAEs of ~69%) is generally consistent with other oral disease-modifying therapies in the MS space.

Stakeholder Impact

• Shareholders: Increased visibility into the clinical profile of the lead asset.
• Patients: Potential for new therapeutic options in progressive MS.

Next Steps

• Continue phase 3 ENSURE trials for relapsing MS.
• Release top-line data for ENSURE trials by end of 2026.

Key Dates

Recommendation

The filing provides incremental scientific data but does not change the fundamental financial or commercial outlook for the company. Investors should wait for the phase 3 top-line data expected later in 2026 before adjusting positions.

Keywords

Immunic, IMUX, vidofludimus calcium, multiple sclerosis, biotechnology, clinical trials, CMSC, neurodegenerative